Omnitrope Shortage: What Providers and Prescribers Need to Know in 2026

The somatropin market has been in flux since late 2022. Multiple brands have faced supply disruptions, and your patients may be asking about Omnitrope availability, requesting therapeutic substitutions, or struggling to navigate insurance hurdles that delay treatment. This briefing consolidates the most current clinical and logistical information to help you manage your growth hormone-dependent patient panel effectively in 2026.

Current Omnitrope Shortage Status (2026)

As of December 2025, Sandoz has confirmed availability of all marketed Omnitrope presentations, and Omnitrope is not listed on the FDA Drug Shortage Database. ASHP's most recent shortage bulletin indicates all Omnitrope cartridge sizes (5 mg/1.5 mL and 10 mg/1.5 mL) and the 5.8 mg vial are available.

However, national supply availability does not translate to frictionless patient access. The most common barriers your patients face are prior authorization requirements, specialty pharmacy network restrictions, and cost — not actual product shortage.

Somatropin Market Context: What's Changed Since 2022?

Since late 2022, the following events have reshaped the somatropin landscape:

• Norditropin supply disruption (2022–2023): Novo Nordisk faced severe supply constraints, forcing widespread patient switching to alternatives.
• Nutropin AQ NuSpin shortage and discontinuation: Genentech reported supply constraints starting August 2023 driven by demand surges. The 30 mg/3 mL size was discontinued in late 2025.
• Pfizer production ramp-up: Pfizer increased Genotropin production 3.5x in 2023 vs. 2022 to address demand.
• Increased demand for Omnitrope: As patients were redirected from shortage brands, Omnitrope saw increased prescribing volume. Sandoz maintained supply, but individual specialty pharmacies experienced localized stock variability.

Prior Authorization Challenges: What Prescribers Need to Know

Prior authorization for somatropin products, including Omnitrope, is standard practice across commercial plans and Medicare Part D. Key PA considerations in 2026:

• Required documentation: Diagnosis codes, IGF-1 levels (ideally with age/sex-adjusted SDS), growth hormone stimulation test results (for GHD), height/weight SD scores (for pediatric patients), and treatment history.
• Renewal cycles: Most plans require annual PA renewal for adult GHD; some require 6-month renewals for pediatric patients. Proactive submission 30 days before expiration prevents treatment gaps.
• Brand-specific PA: If a patient switches from another somatropin brand to Omnitrope (or vice versa), a new brand-specific PA is generally required even if the diagnostic PA is already on file. Budget additional time for these.
• Step therapy: Some plans require trial and failure of a formulary-preferred brand before covering Omnitrope. Familiarize yourself with each major payer's step requirements in your patient population.

Clinical Guidance: When to Switch and What to Switch To

All daily somatropin products contain recombinant human growth hormone with the same 191-amino-acid sequence. Therapeutic switching between brands is clinically equivalent, though patients should be retrained on the new delivery device and may require a dose recalculation (weight-based dosing remains the same).

Clinical considerations when recommending a switch from Omnitrope:

• Norditropin (Novo Nordisk): Most commonly preferred on formularies. FlexPro pen does not require cartridge changes. Approved for all Omnitrope indications plus Noonan Syndrome.
• Genotropin (Pfizer): MiniQuick option allows up to 3 months of room-temperature storage — useful for patients with travel or refrigeration challenges.
• Humatrope (Eli Lilly): Consider for patients with SHOX deficiency — the only somatropin product approved for this specific indication.
• Skytrofa (Ascendis Pharma): Once-weekly long-acting somatropin prodrug for pediatric GHD. Consider for patients with compliance challenges. Not approved for adult GHD.

Patient Assistance Resources to Share

Sandoz's OmniSource program provides comprehensive support for Omnitrope patients:

• Co-Pay Savings Program: Commercially insured patients may pay as little as $0/month.
• Self-Pay Program: Uninsured or commercially uninsured patients pay $19/mg.
• Interim Bridge Supply: Commercially insured patients can receive free Omnitrope for up to 1 full year if insurance authorization is delayed more than 10 business days.

OmniSource contact: 877-456-6794 | omnitrope.com

How medfinder Supports Your Patients

When your patients can't find Omnitrope at their local or specialty pharmacy, medfinder is a service that calls pharmacies near them on their behalf to identify which ones can fill the prescription. Results are texted directly to the patient. Directing struggling patients to medfinder can reduce your staff's call volume for pharmacy-related questions. Learn more at medfinder.com/providers.

Key Takeaways for Prescribers

• Omnitrope is not in a formal shortage as of 2026; Sandoz has confirmed availability of all presentations
• Prior authorization and specialty pharmacy restrictions are the primary access barriers — not drug supply
• Proactive PA renewal (30 days before expiration) prevents treatment gaps
• All daily somatropin brands are therapeutically interchangeable; retrain patients on new device if switching
• Direct cost-burdened patients to OmniSource (877-456-6794) for savings programs and bridge supply